aTyr Pharma, Inc.
aTyr Pharma, Inc.
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | Fibrosis, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, connective tissue disorder, interstitial lung disease, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2025-05-07 | NCT05892614 |